{
    "2020-07-15": [
        [
            {
                "time": "",
                "original_text": "君实开盘市值破1500亿！采用“新主流”估值，65亿研发投入的百济为何不敌恒瑞、信达、贝达们？",
                "features": {
                    "keywords": [
                        "君实",
                        "市值",
                        "1500亿",
                        "新主流估值",
                        "百济",
                        "恒瑞",
                        "信达",
                        "贝达",
                        "研发投入"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "生物医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            }
        ]
    ]
}